Lyomark Pharma GmbH

Alveofact is used in neonates. Preventive use in premature neonates with a high risk of respiratory distress syndrome (RDS).
Active substance: Phospholipid fractionfrom bovine lung (surfactant)

Neofact is an innovative applicator for instillation of surfactant and is used for the management of respiratory distress syndrome (RDS) in preterm and term neonates:

• Simple and practical handling • Application of surfactant without Magill forceps • Precise positioning in fro...

Neofact, by Lyomark Pharma, is a medical device for neonates suffering from RDS. 
This study shows that the LISA method (less invasive surfactant administration) via Neofact® appears feasible. 

Neofact® makes surfactant application easy and is also suitable for all gestatio...

Octreotid Bendalis 0.05 mg/ml
Octreotid Bendalis 0.1 mg/ml
Octreotid Bendalis 0.5 mg/ml
Octreotid Bendalis 0.2 mg/ml

Somatostatin 3mg

Powder for solution for infusion

Vancomycin Lyomark 500 mg and 1000mgPowder for concentrate for solution for infusion or oral solution.

Lyomark Pharma Ltd offers a wide range of services which includes active ingredients service. It collaborates with leading pharmaceutical manufacturers from around the world in the development and marketing of pharmaceutical raw materials and active ingredients. It helps to market analysis and choosing the ri...

Lyomark Pharma Ltd offers a wide range of services which includes distribution services. It distributes since 2007 its own products directly in the german hospital market. In addition to direct sales in germany will award it also has distribution licenses to international distribution partner for the worldwid...

Lyomark Pharma Ltd offers a wide range of services which includes manufacturing services. It has been working for many years with reliable and internationally operating contract manufacturers. Each product is constantly accompanied by the development, on the approval and production to ready-made sales of good...

Lyomark Pharma Ltd offers a wide range of services which includes regulatory services. It offers different regulatory services to clients from the pharmaceutical industry. In addition to the provision of our products and the dossiers based on submission of approvals and following further services are availabl...

Neofact, by Lyomark Pharma, is a medical device for neonates suffering from RDS. 
This study shows that the LISA method (less invasive administration) via Neofact® appears feasible. 

Neofact® makes surfactant application easy and can also be used at any gestational age.

https://pubmed.ncbi.nlm.nih.gov/33023914/

 Avoidance of plastic waste - New packaging for Alveofact®

In the clinical study carried out at the University Hospital Tübingen, 20 premature infants (gestational age ≥26 + 0/7) were administered surfactant Alveofact® (45 mg / mL; Lyomark Pharma, Oberhaching, Germany) using the new LISA application aid Neofact®. The aim of developing Neofact® was to enable a simple and gentle process for surfactant application that works without the use of Magill forceps. Neofact® makes surfactant application easy and is also suitable for all gestational ages. This was confirmed in the study and the results of the study are convincing. An extremely high success rate could be achieved (95%), complications seemed rear.

Further information on the study can be found: https://pubmed.ncbi.nlm.nih.gov/33023914/